SNCA and Parkinson disease: This study demonstrated that, functionally, the reduction in α-synuclein rescued mitochondrial dysfunction and cellular defects, which were consequential of α-synuclein overexpression, indicating at the possibility of utilising the peptide PROTAC as a potential strategy to treat PD.